Danielle Bargo is a Health Economist in the pharmaceutical industry with over 10 years of experience generating and using evidence to inform drug pricing and reimbursement decisions globally. Danielle is currently a Director in the Real World Evidence and Health Economics and Outcomes Research team at Eisai, and an advisor on the Patient-Centered Outcomes Research Institute (PCORI) Clinical Effectiveness and Decision Science advisory panel. Prior to Eisai, she was the Head of Health Technology Assessments at Flatiron Health and a Global HEOR Lead at Pfizer.

Danielle earned a BA in Political Science from Butler University, a MSc in Social Policy from the London School of Economics and Political Science and is currently a Doctor of Public Health student in Health Policy at the Johns Hopkins Bloomberg School of Public Health.